William Blair upgraded Argenx (ARGX) to Outperform from Market Perform following the Q3 report. The firm says that with the “clear outperformance” of the Vyvgart franchise in myasthenia gravis and the launch of chronic inflammatory demyelinating polyneuropathy, it sees a growth trajectory for Argenx to maintain recently achieved breakeven and profitability. The firm also sees value in the company’s clinical assets, such as empasiprubart as well several “pipeline-in-a-drug opportunities.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
- Argenx Reports Strong Q3 2024 Financial Results
- Argenx price target raised to $660 from $540 at Truist
- Argenx SE’s Strong Q3 Results and Future Outlook
- Argenx reports Q3 EPS $1.39, consensus 3c
- Is ARGX a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
